Radiopharmaceuticals and Tracers

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates...

Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 10, 2017 | Anamika Kumari

Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial...

X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg
News | Radiopharmaceuticals and Tracers | March 09, 2017

March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health...

Navidea, Lymphoseek, North American rights, sale, Cardinal Health
News | Radiopharmaceuticals and Tracers | March 08, 2017

Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to Cardinal Health....

PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017

March 3, 2017 — In the featured article of the March 2017 issue of...

News | Radiopharmaceuticals and Tracers | February 16, 2017

Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the...

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017

Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will...

radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017

A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...

IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017

IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...

News | Radiopharmaceuticals and Tracers | January 17, 2017

NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s ...

Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017

January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source...

News | Radiopharmaceuticals and Tracers | January 06, 2017

New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer...

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017

Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a...

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States...

prostate, CT scan
News | Prostate Cancer | December 22, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics...

News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that...

News | Nuclear Imaging | December 12, 2016

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be...

Alzheimer's disease, early diagnosis, PET scans, imaging compound, Fluselenamyl

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects the Alzheimer’s protein amyloid beta better than current FDA-approved agents. The compound potentially may be used in brain scans to identify people in the earliest stages of Alzheimer’s disease. In the image, the compound has passed from the bloodstream of a living mouse into its brain, where it is detected by a positron emission tomography (PET) scan. Arrows indicate clumps of amyloid beta. Credit Ping Yan and Jin-Moo Lee.

News | Radiopharmaceuticals and Tracers | November 02, 2016

November 2, 2016 — By the time unambiguous signs of memory loss and cognitive decline appear in people with...

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers | October 28, 2016

The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of...

Axumin, fluciclovine F-18, PET agent, Phase 3 study, recurrent prostate cancer detection, Blue Earth Diagnostics
News | Prostate Cancer | October 25, 2016

Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a Phase 3 clinical trial of...

Overlay Init